| |
 |
|
|
|
|
| Eisai Establishes Pharmaceuticals Marketing Subsidiary in Switzerland |
|
|
|
Tokyo, June 9, 2005 (JCN) - Eisai (TSE: 4523) announced on June 6 that it has established a pharmaceuticals marketing subsidiary in Switzerland through its European operation subsidiary Eisai Europe.
Capitalized at 3 million swiss fran ($2.4 mil), Eisai Pharma AG will sell pharmaceuticals mainly in the neurology area. The company will also be responsible for submitting applications for anti-epileptic drugs Zonegran and Inovelon in Switzerland in the future.
The new foothold in Switzerland, where steady growth is anticipated in the pharmaceutical market, will serve as a node in the sales network Eisai is stepping up its drive to expand for its products in Europe.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
|
|
Eisai Announces Preclinical Research Findings Suggesting Novel Infibitory Effect on Tumor Metastasis for Anticancer Agent Halaven(R) at AACR 104th Annual Meeting
(Apr 10, 2013)
|
|
|
Eisai Co-establishes the Global Health Innovative Technology Fund
(Apr 8, 2013)
|
|
|
Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Planned Direct Sales Launch in Russia
(Apr 5, 2013)
|
|
|
Eisai to Launch Botulinum Toxin Type B Neuromuscular-Blocking Agent Nerbloc(R) intramuscular Injection 2500 Units in Japan
(Mar 26, 2013)
|
|
|
Eisai Recieves Manufacturing and Marketing Authorization for Antiepileptic Agent Inovelon(R) in Japan
(Mar 25, 2013)
|
|
|
Eisai Announces Launch of Chocola BB(R) Sparkling + Fiber, Containing 5 Ingredients that Help Bring Out Beauty from Within
(Feb 26, 2013)
|
|
|
Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer
(Jan 11, 2013)
|
|
|
Noblepharma and Eisai Announce Japan Lunch of Antineoplastic Agent Gliadel(R) 7.7 mg Implant
(Jan 8, 2013)
|
|
|
Eisai Signs Agreement with Epizyme and Roche Molecular Systems to Develop Companion Diagnostic
(Jan 8, 2013)
|
|
|
Eisai Signs Global Agreement with Fundacao Oswaldo Cruz to Begin Development of New Medicines and Vaccines for Malaria and Neglected Tropical Diseases
(Oct 25, 2012)
|
|
|
|
|
|
|
|
|
|
|
